Cosmo Pharmaceuticals NV
Cosmo Pharmaceuticals's GHG Emissions Data Preview
In 2024, Cosmo Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).
However, Cosmo Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Cosmo Pharmaceuticals's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of Cosmo Pharmaceuticals amounted to 5,714.27 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Cosmo Pharmaceuticals increased by 7.23%, suggesting that the company faced challenges in reducing its emissions from its core operations.
Cosmo Pharmaceuticals's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Cosmo Pharmaceuticals's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Cosmo Pharmaceuticals were 5,657.69 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Compared to the previous year (2023), Cosmo Pharmaceuticals's Scope 1 emissions increased by 7.24%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.
What are Cosmo Pharmaceuticals's Scope 2 emissions?
In 2024, Cosmo Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 56.58 tCOâ‚‚e without specifying the calculation method.
Has Cosmo Pharmaceuticals reduced its Scope 2 emissions over time?
Compared to the previous year (2023), Cosmo Pharmaceuticals's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Cosmo Pharmaceuticals 's emissions have plateaued with no significant change in its energy consumption footprint.
What methodology does Cosmo Pharmaceuticals use for Scope 2 reporting?
In 2024, Cosmo Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.
Cosmo Pharmaceuticals's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)